(Q34657978)

3 August 2017

1 reference

title

BCG (Bacillus of Calmette Guerin) therapy of high-risk superficial bladder cancer (English)

1 reference

3 August 2017

PierFrancesco Bassi

1

1 reference

3 August 2017

1 June 2002

1 reference

3 August 2017

1 reference

3 August 2017

11

1 reference

3 August 2017

77-83

1 reference

3 August 2017

1-2

1 reference

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Natural history and treatment of low and high risk superficial bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Superficial bladder cancer: progression and recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Radical cystectomy--often too late?

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

BCG in perspective: advances in the treatment of superficial bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Improving the safety of BCG immunotherapy by dose reduction. Cooperative Group CUETO.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Low Dose Pasteur Bacillus Calmette-Guerin Regimen in Stage T1, Grade 3 Bladder Cancer Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Intravesical Chemotherapy (Mitomycin C) versus Immunotherapy (Bacillus Calmette-Guérin) in Superficial Bladder Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Superficial transitional cell carcinoma of the bladder associated with mucosal involvement of the prostatic urethra: results of treatment with intravesical bacillus Calmette-Guerin

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Intravesical bacillus Calmette-Guerin therapy for in situ transitional cell carcinoma involving the prostatic urethra

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Intravesical bacillus Calmette-Guerin for the treatment of superficial transitional cell carcinoma of the prostatic urethra in association with carcinoma of the bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

Intravesical Bacillus Calmette-Guérin with the Danish strain for treatment of carcinoma in situ of the bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

In situ transitional cell carcinoma involvement of prostatic urethra: bacillus Calmette-Guérin therapy without previous transurethral resection of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2802%2900008-7

7 January 2021

10.1016/S0960-7404(02)00008-7

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

12031870